A Strategic Plan for the Second Phase (2013–2015) of the Korea Biobank Project

Abstract

The Korea Biobank Project (KBP) was led by the Ministry of Health and Welfare to establish a network between the National Biobank of Korea and biobanks run by university-affiliated general hospitals (regional biobanks). The Ministry of Health and Welfare started the project to enhance medical and health technology by collecting, managing, and providing researchers with high-quality human bioresources. The National Biobank of Korea, under the leadership of the Ministry of Health and Welfare, collects specimens through various cohorts and regional biobanks within university hospitals gather specimens from patients. The project began in 2008, and the first phase ended in 2012, which meant that there needed to be a plan for the second phase that begins in 2013. Consequently, professionals from within and outside the project were gathered to develop a plan for the second phase. Under the leadership of the planning committee, six working groups were formed to formulate a practical plan. By conducting two workshops with experts in the six working groups and the planning committee and three forums in 2011 and 2012, they have developed a strategic plan for the second phase of the KBP. This document presents a brief report of the second phase of the project based on a discussion with them.During the first phase of the project (2008–2012), a network was set up between the National Biobank of Korea and 17 biobanks at university-affiliated hospitals in an effort to unify informatics and governance among the participating biobanks. The biobanks within the network manage data on their biospecimens with a unified Biobank Information Management System. Continuous efforts are being made to develop a common standard operating procedure for resource collection, management, distribution, and personal information security, and currently, management of these data is carried out in a somewhat unified manner. In addition, the KBP has trained and educated professionals to work within the biobanks, and has also carried out various publicity promotions to the public and researchers. During the first phase, biospecimens from more than 300,000 participants through various cohorts and biospecimens from more than 200,000 patients from hospitals were collected, which were distributed to approximately 600 research projects.The planning committee for the second phase evaluated that the first phase of the KBP was successful. However, the first phase of the project was meant to allow autonomy to the individual biobanks. The biobanks were able to choose the kind of specimens they were going to collect and the amount of specimen they would set as a goal, as well as being allowed to choose their own methods to manage their biobanks (autonomy). Therefore, some biobanks collected resources that were easy to collect and the resources needed by researchers were not strategically collected. In addition, there was also a low distribution rate to researchers outside of hospitals, who do not have as much access to specimens and cases as those in hospitals. The...

A compilation of national plans, policies and government actions for rare diseases in 23 countries

“…In 1991, Singapore implemented the Medicines Act (Chapter 176, Section 9) which focuses on managing, and encouraging the use of, orphan drugs (34). In 2003, South Korea created the Orphan Drugs Guideline (35) and, in 2013, the Korea Biobank Project (KBP) for rare disease (36). In Taiwan, the Rare Disease and Orphan Drug Act provides support for rare disease patients by encouraging rare disease research, and increasing awareness of rare disease (25,37).…”

“…Country Australia (1)(2)(3)10,29,32,35,39,51) China (1,25,30-32, 35,71) Japan (1)(2)(3)8,10,32,35,39,51,57,(67)(68)(69) Philippines (32,33,70) Singapore (1,2,32,34) South Korea (32,35,36,67) Taiwan (1,2,25,32,35,37,57,67) China pilot project: to provide and use guidelines, create registries and encourage molecular testing for rare diseases. This project seeks to build relationships with collaborative networks, clinicians and patient organizations.…”

Biobanco: Herramienta fundamental para la investigación biomédica actual

“…En la misma vía, el Visiongain, un portal líder de información de negocios, con sede en Londres, Reino Unido, predice que el mercado mundial de los biobancos en la medicina humana generará $ US 24,4 mil millones en 2017 y una fuerte expansión hasta 2023 21 . 22,23 .…”

Development of an Integrated Biospecimen Database among the Regional Biobanks in Korea

“…Each biobank can enter and manage human bio-data using the BIMS operated by the NBK. However, the BIMS manages the bio-data information by using a form limited to 18 items [ 17 ]. Since each biobank was designed to gather information independently for a prolonged period after its establishment, the biobanks share information with each other in spreadsheets.…”